Cosmos Health completes acquisition of ten-drug portfolio

Cosmos Health has completed the acquisition of the licenses and rights of a comprehensive portfolio of 10 generic drugs from a related party for EUR 3.2 million, or approximately $3.5 million at today’s exchange rate. This strategic acquisition significantly enhances Cosmos Health’s pharmaceutical portfolio. The selected drugs have been chosen for their efficacy in addressing a variety of health issues, including treatments for diabetes, cholesterol, respiratory, and cardiac conditions, among other critical health areas. This diverse selection underlines Cosmos Health’s unwavering commitment to providing diverse medical needs through comprehensive, patient-centric healthcare solutions, catering to the specific needs of patients across multiple medical domains. All medicines will be manufactured at the facilities of the Company’s wholly-owned subsidiary, Cana Laboratories.